BACKGROUND: The regulation of appetite and food intake in birds are implemented as complex homeostatic mechanisms at different levels of control. OBJECTIVES: The current research aimed to investigate the effects of glycine and strychnine-sensitive receptors on food intake induced with dopamine in neonatal broiler-type chickens. METHODS: This study was conducted in five experiments (each consisting of four treatment groups with 12 birds). In experiment 1, chickens in the control group received intracerebroventricular (ICV) injection of saline (with 0.1 % Evans Blue) and different doses of dopamine (10, 20, and 40 nmol) in treatments groups 2-4, respectively. Experiments 2 and 3 were designed similar to the experiment 1 except for the fact that chickens received different doses of glycine (50, 100, and 200 nmol) and strychnine (50, 100, and 200 nmol) instead of dopamine. Experiment 4 was performed to investigate the mediatory role of strychnine (100 nmol) on food intake induced with dopamine (40 nmol). Moreover, experiment 5 investigated the interaction between non-effective doses of glycine (50 nmol) and dopamine (10 nmol) and their interplay on food intake. Afterwards, cumulative food intake based on bodyweight percentage (BW %) was measured at 30, 60, and 120 minutes after the injection. RESULTS: The obtained findings revealed that effective doses of dopamine and glycine dose-dependently induced hypophagia in neonatal meat-type chickens (p < /em>≤0.05). In addition, injection of strychnine increased food intake and also inhibited the hypophagic effect induced by dopamine (p < /em>≤0.05). Furthermore, co-administration of non-effective doses of glycine and dopamine significantly decreased food intake compared to the groups which only received dopamine or glycine (p < /em>≤0.05). CONCLUSIONS: Our findings suggested that strychnine-sensitive receptors may have a mediatory role in food intake induced by dopamine. Additionally, it seems that glycine and dopamine probably have synergistic effects on food intake control in neonatal meat-type chickens.

Xylazine, a type of α₂-adrenoceptors, is a commonly used drug in veterinary medicine. Xylazine-induced changes in the content of amino acid neurotransmitters – glycine (Gly) and aspartic acid (Asp), in different brain regions and neurons were studied. Wistar rats were administered 50 mg/kg or 70 mg/kg of xylazine by intraperitoneal injection. In addition, in vitro experiments were conducted, in which neurons were treated with 15 μg/mL, 25 μg/mL, 35μg/mL, and 45 μg/mL of xylazine. Test methods were based on the enzyme-linked immunosorbent assays (ELISA). During anaesthesia, Asp levels in each brain area were significantly lower compared to the control group. Except for the cerebrum, levels of Gly in other brain areas were significantly increased during the anaesthesia period. In vitro, xylazine-related neuron secretion of Gly increased significantly compared to the control group at 60 min and 90 min. Moreover, xylazine caused a significant decrease in the levels of Asp secreted by neurons at 20 min, but gradually returned to the level of the control group. The data showed that during anaesthesia the overall levels of Asp decreased and overall levels of Gly increased. In addition, the inhibitory effect of xylazine on Asp and the promotion of Gly were dose-dependent. Our data showed that different effects of xylazine on excitatory and inhibitory neurotransmitters provided a theoretical basis for the mechanism of xylazine activity in clinical anaesthesia.

Xylazine, a type of α2-adrenoceptors, is a commonly used drug in veterinary medicine. Xylazine-induced changes in the content of amino acid neurotransmitters – glycine (Gly) and aspartic acid (Asp), in different brain regions and neurons were studied.

Concentrations of amino acids in the plasma of 13 neonatal foals with septicemia were compared with the concentrations of amino acids in the plasma of 13 age-matched neonatal foals without septicemia. Analysis of the results revealed significantly lower concentrations of arginine, citrulline, isoleucine, proline, threonine, and valine in the plasma of foals with septicemia. The ratio of the plasma concentrations of the branched chain amino acids (isoleucine, leucine, and valine) to the aromatic amino acids (phenylalanine and tyrosine), was also significantly lower in the foals with septicemia. In addition, the concentrations of alanine, glycine, and phenylalanine were significantly higher in the plasma of foals with septicemia. Therefore, neonatal foals with septicemia had significant differences in the concentrations of several amino acids in their plasma, compared with concentrations from healthy foals. These differences were compatible with protein calorie inadequacy and may be related to an alteration in the intake, production, use, or clearance of amino acids from the plasma pool in sepsis.

Several pharmaceutical compounds were evaluated for their ability to selectively inhibit activated coagulation factor-XIII-like enzyme activity (eg, XIIIa) in pooled equine plasma. Presence of coagulation factor-XIIIa -like enzyme activity in plasma was established by assay procedures involving incorporation of the fluorescent amine compound, monodansylcadaverine, into purified casein, which served as a protein substrate. Pharmaceuticals inhibitory to coagulation factor-XIIIa -like enzyme activity were recognized by plasma gel formation of high spectrophotometric transmittance (transparency), solubility of transparent fibrin gels in concentrated urea solution, in conjunction with simultaneous depletion of native fibrinogen fractions, and production of fibrin monomer. Compounds acting primarily as anticoagulants were recognized by lack of plasma gel formation, but retaining high spectrophotometric transmittance and no detectable depletion of native fibrinogen fractions. Compounds failing to inhibit either thrombin-mediated fibrinogen-fibrin transformation (ie, coagulation) or coagulation factor-XIIIa -like enzyme activity were recognized by opaque plasma gels caused by fibrin polymerization, low spectrophotometric transmittance values, and coinciding with depletion of native fibrinogen fractions. Pharmaceuticals capable of exerting selective inhibition of coagulation factor-XIIIa -like enzyme activity were further classified as competitive inhibitors of phase 1 (carbamide) or phase 2 (terminal amine) of the transglutamination process.